Dr. Wigard Kloosterman

Co-founder and Chief Scientific Officer - Cyclomics

Wigard Kloosterman holds a PhD in Molecular Biology (2007) from Utrecht University. Until 2019, he was an Associate Professor at the Department of Genetics at the University Medical Center Utrecht, leading a research group in cancer genomics, with particular focus on understanding complex genomic variants and their contribution to cancer phenotypes, such as drug response. He contributed to bringing knowledge from cancer genomics research to the clinic. Furthermore, Dr Kloosterman is a leading expert in genome sequencing technology, including computational analysis, and he has contributed multiple seminal papers in this field. He is at the forefront of implementing third-generation nanopore sequencing technology in research and clinical settings. Besides his role within Cyclomics, Dr. Kloosterman is appointed as CSO of Frame Cancer Therapeutics, an immunotherapy start-up in Amsterdam, aiming for development of personalised cancer vaccines.

Got a question for Dr. Wigard Kloosterman?

Get in touch using the contact form linked here and we’ll get back to you shortly

Published Content

Total: 1

Webinar

The Most Comprehensive Insights in Cancer Genomes: Translational Research

This symposium brings together world-leading experts in cancer research and translational medicine to showcase how nanopore sequencing technology is being utilized to identify novel disease biomarkers.

From the characterization of small biomarkers, like circulating tumor DNA and single-nucleotide variants, to large structural variants and base modifications, nanopore sequencing delivers comprehensive insights into the cancer genome.

The speakers will discuss targeted and genome-wide detection of circulating tumor DNA, exploration of brain tumors and sarcomas and how nanopore sequencing has advanced their research.